A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure

Currently, the early introduction of new antiandrogens is popular for castration-resistant prostate cancer (CRPC). However, adverse events can be severe and their costs are high. Here, we present a patient with CRPC in whom flutamide controlled disease progression for 10 years. This case report show...

Descripción completa

Detalles Bibliográficos
Autores principales: Muramatsu, Tomoaki, Funahashi, Yasuhito, Yamamoto, Akiyuki, Sassa, Naoto, Matsukawa, Yoshihisa, Gotoh, Momokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892669/
https://www.ncbi.nlm.nih.gov/pubmed/31849389
http://dx.doi.org/10.18999/nagjms.81.4.707
Descripción
Sumario:Currently, the early introduction of new antiandrogens is popular for castration-resistant prostate cancer (CRPC). However, adverse events can be severe and their costs are high. Here, we present a patient with CRPC in whom flutamide controlled disease progression for 10 years. This case report shows that conventional alternative antiandrogens are cost effective and are still an important option for the treatment for CRPC.

Ejemplares similares